Regular ArticlePlatelet anaesthesia during extracorporeal circulation: Differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia☆
Introduction
Contact of blood with an extracorporeal circulation circuit (ECC) and exposure of blood to hypothermia as employed in cardiac surgery causes persistent activation and subsequent dysfunction of platelets [1], [2], [3]. Temporary blockade of the main platelet receptor GP IIb/IIIa (αIIbβ3) during ECC, also termed “platelet anaesthesia”, is an experimental pharmacological strategy to protect platelets during ECC [4]. It is not yet routinely employed but may be very beneficial for the clinical setting and improve the outcome of operations employing ECC. Several studies have shown that cardiac surgery can be performed without an increase of bleeding complications after administration of short-acting GP IIb/IIIa blockers [5], [6], [7]. A desirable property of a GP IIb/IIIa blocker used as “platelet anaesthetic” is a short half-life. Thereby platelets are inhibited only during ECC and full platelet function is restored shortly after ECC to provide full functioning platelets for haemostasis at the end of surgery. According to this criterion the “ultra-short acting” GP IIb/IIIa blocker FK633 would be very suitable because of its half-life of only 0.52 h [8]. GP IIb/IIIa blockers that are also candidates for “platelet anaesthesia” are the commercially available agents tirofiban and eptifibatide. Nevertheless, both are not optimal for the desired indication because of their half-lives of 1.5–2 h [9]. Therefore, it is not clear which agent would be most suitable for “platelet anaesthesia”. This issue is very important not only in terms of half-life of the desired agent but also regarding the fact that GP IIb/IIIa blockers may induce platelet activation under certain conditions [10], [11], [12], [13]. In general, a platelet-activating property may limit the efficiency of an anti-platelet drug. The aim of this study was to investigate potentially platelet-activating effects of the GP IIb/IIIa blockers FK633, tirofiban and eptifibatide under conditions of ECC at normothermia and hypothermia as employed in cardiac surgery.
Section snippets
Blood sampling
Blood from non-medicated healthy male subjects, definitely free of platelet-affecting drugs for 14 days, was collected by venipuncture with a 21 gauge butterfly needle from an antecubital vein. The first 5 mL of blood was discarded before additional blood samples were drawn for analysis. All blood samples were anti-coagulated with 3 U/mL heparin. Blood sampling procedures were approved by the ethics committee of the University of Tübingen, Germany (project-numbers 410/2004 V and 193/2002 V).
Sample preparation
In
Expression of the platelet activation marker P-selectin
During ECC platelet activation is induced by contact activation of platelets at the artificial ECC surface. A strong temperature-associated effect was observed regarding the action of GP IIb/IIIa blockers on P-selectin:
After 30 and 90 min of normothermic ECC FK633 inhibited P-selectin expression in unstimulated and ADP-stimulated samples (Fig. 1a). During hypothermic ECC FK 633 treatment increased P-selectin expression 3.2-fold in unstimulated samples (after 30 min) and 2.7-fold (after 90 min)
Discussion
Blood circulation in an ECC circuit and hypothermia in temperature ranges as applied in cardiac surgery leads to damage and dysfunction of platelets [2], [3]. Previous reports have stated that pharmacological platelet anaesthesia using a blocker of the main platelet receptor GP IIb/IIIa can protect platelets against ECC-induced damage [4], [15]. The principle of platelet anaesthesia comprises that a GP IIb/IIIa blocker is administered temporarily before or during ECC to protect platelets
Conclusion
Ultra-short acting GP IIb/IIIa blockade with FK633 is a promising experimental strategy to inhibit platelet activation and thereby conserve platelet function during normothermic ECC. However, in temperature ranges of deep hypothermia that may be applied during cardiac surgery GP IIb/IIIa inhibitors like FK633 and eptifibatide induce expression of the platelet activation marker P-selectin which suggests a prothrombotic side effect of these agents. Therefore, a potential GP IIb/IIIa blocker for
References (23)
- et al.
Biphasic pro-thrombotic and inflammatory responses after coronary artery bypass surgery
J Thromb Haemost
(2003) - et al.
The platelet in cardiopulmonary bypass
Ann Thorac Surg
(1998) - et al.
Tirofiban provides “platelet anesthesia” during cardiopulmonary bypass in baboons
J Thorac Cardiovasc Surg
(1997) - et al.
Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting
J Thorac Cardiovasc Surg
(2001) - et al.
Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery
J Thorac Cardiovasc Surg
(2001) - et al.
The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIB/IIIA antagonist
Thromb Res
(1996) - et al.
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors
Blood
(1998) - et al.
Differential antiplatelet effects of various glycoprotein IIb–IIIa antagonists
Thromb Res
(2001) - et al.
Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation
J Thorac Cardiovasc Surg
(2003) - et al.
The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor
Thromb Res
(2004)
Cited by (16)
Developing standards and test protocols for testing the hemocompatibility of biomaterials
2018, Hemocompatibility of Biomaterials for Clinical Applications: Blood-Biomaterials InteractionsDeveloping standards and test protocols for testing the hemocompatibility of biomaterials
2017, Hemocompatibility of Biomaterials for Clinical Applications: Blood-Biomaterials InteractionsProgress in platelet blockers: The target is the P2Y<inf>12</inf> receptor
2013, Journal of Cardiothoracic and Vascular AnesthesiaCitation Excerpt :This trial demonstrated that cangrelor can maintain perioperative platelet blockade in high-risk patients without significant bleeding risk. The intense but reversible parenteral platelet blockade due to cangrelor can provide platelet anesthesia during cardiopulmonary bypass to reduce bleeding and transfusion thereafter due to enhanced platelet function.44,45 This pharmacokinetic hypothesis recently was tested in a large animal model with hypothermic cardiopulmonary bypass.46
Short-acting P<inf>2</inf>Y<inf>12</inf> blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia
2012, British Journal of AnaesthesiaCitation Excerpt :Previous reports described a protective effect using GPIIb/IIIa blockers during ECC and hypothermia.7 13 22 However, the most short-acting GPIIb/IIIa blockers that are commercially available (tirofiban and eptifibatide) are not ideal agents for platelet protection during ECC because of high postoperative bleeding risks due to their long half-lives of 1.5–2 h.7 23 Furthermore, GPIIb/IIIa blockade can be associated with a paradoxical platelet-activating effect possibly resulting in thrombotic events.7 24 25 Therefore, the establishment of new anti-platelet strategies for platelet protection during ECC is of major importance.
Postoperative hypothermia in surgical patients at Azadi teaching hospital
2020, Medico-Legal Update
- ☆
This work has been presented at the Annual Scientific Meeting of the Australian Vascular Biology Society at Bellinzona, Hepburn Springs, Victoria on the 7th of September 2007.